期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (6)
Purpose Macrophage apoptosis coupled with a defective phagocytic clearance of the apoptotic cells promotes plaque necrosis in advanced atherosclerosis......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Purpose Diabetes mellitus (DM) is a major risk factor for the development of heart failure (HF). Sodium-glucose co-transporter 2 (SGLT2) inhibitors ha......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (1)
Background Acute coronary syndrome (ACS) is a serious and life-threatening condition. Anticoagulation during the acute phase of ACS is effective in re......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (3)
Purpose The extent of myocardial fibrosis is closely related to the prognosis of diabetic cardiomyopathy (DCM). Low-intensity pulsed ultrasound (LIPUS......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (1)
Purpose To determine the association between low molecular weight heparin (LMWH) use and mortality in hospitalized COVID-19 patients. Methods We condu......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (1)
Hypertension, a chronic and progressive disease, is an outstanding public health issue that affects nearly 40% of the adults worldwide. The increasing......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (2)
Pulmonary arterial hypertension (PAH) is a progressive disease with a complex aetiology and high mortality. Functional and structural changes in the s......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (1)
Purpose Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP). The present study is to quantitatively a......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Background Drug-coated balloon (DCB) has been proved efficacy for coronary small vessel disease, but data regarding outcomes of DCB in common de novo ......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (6)
Purpose Anti-inflammatory therapy is important for reducing myocardial injury after acute myocardial infarction (MI). New anti-inflammatory drugs and ......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (3)
Purpose The CD36 scavenger receptor is a mediator of both atherogenesis and thrombosis. We aimed to investigate the prognostic value of CD36+ micropar......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (3)
Background Heart failure (HF) is one of the most serious health concerns worldwide. Anemia is a highly prevalent comorbidity and outcome predictor in ......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (5)
Purpose It has been established that obstructive sleep apnea (OSA) is an independent risk factor for atherosclerosis. Chronic intermittent hypoxia (CI......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (3)
Purpose Ketone body oxidation yields more ATP per mole of consumed oxygen than glucose. However, whether an increased ketone body supply in hypoxic ca......
